Deep Genomics
A biotechnology company that uses its BioFM biological foundation model platform to discover targets and design genetic medicines. It runs its own drug discovery programs and research partnerships rather than selling a software product that businesses can sign up to.
● Use Cases
- →Identifying new drug targets from genetic data
- →Designing RNA-based therapeutic candidates
- →Research partnerships with pharmaceutical companies
- →Predicting how genetic variants affect RNA processing
● Tags
● Listed In
About Deep Genomics
What is Deep Genomics?
A biotechnology company that uses its BioFM biological foundation model platform to discover targets and design genetic medicines. It runs its own drug discovery programs and research partnerships rather than selling a software product that businesses can sign up to. Deep Genomics is an AI healthcare tool that supports clinical workflows, administrative tasks, patient communication, and medical data analysis — always operating within healthcare compliance frameworks.
Deep Genomics is relevant mainly to Australian biotech companies, universities and medical research institutes looking at drug discovery partnerships, not to general businesses. Any collaboration involving human genomic data raises Privacy Act 1988 obligations for sensitive information, as well as ethics approvals under the National Statement on Ethical Conduct in Human Research. Candidates reaching clinical trials in Australia follow TGA and ethics committee processes. Check intellectual property ownership carefully in any partnership agreement.
How Australian Businesses Use Deep Genomics
Australian healthcare providers use AI tools for appointment scheduling, clinical note transcription, patient triage, insurance verification, and literature review — freeing clinical staff to focus on direct patient care.
Key Features
- ✓BioFM biological foundation model platform for target and molecule discovery
- ✓Focus on RNA biology and genetic medicines
- ✓In-house drug discovery programs
- ✓Research partnerships and licensing with pharmaceutical companies
- ✓Prediction of how genetic variants affect RNA processing
Best For
- →Pharmaceutical companies seeking genetic medicine discovery partners
- →Biotech firms exploring RNA-targeted therapeutic programs
- →Research institutes interested in AI-led target discovery collaborations
Pros & Cons of Deep Genomics
✓ Strengths
- +Specialised in RNA biology and the design of genetic medicines
- +Builds its own biological foundation models
- +Operates as a research partner for pharmaceutical drug discovery programs
- +Established research team with published work
⚠ Limitations
- –No self-serve product or software subscription for businesses to buy
- –Only relevant to drug discovery organisations
- –Partnership terms are negotiated case by case with each organisation
Pricing
There is no product to buy or subscribe to. Access to its platform is through research collaborations and licensing deals with pharmaceutical and biotech organisations. Enquiries go through deepgenomics.com.
Details checked against the vendor's website in October 2026. Pricing changes often, so confirm current plans at deepgenomics.com.
Data Residency & Privacy in Australia
Deep Genomics does not offer a hosted product, so there is no public data residency option to choose. Data handling is set out in each research collaboration agreement. Australian partners sharing human genomic or clinical data should negotiate where data is stored and processed, de-identification standards, permitted uses, and ethics approvals before any transfer, as genomic data is sensitive information.
Need AI that keeps client data onshore? See private AI hosted in Australia.
Getting Started with Deep Genomics in Australia
Deep Genomics is available directly at deepgenomics.com. Verify the tool's compliance with Australian Privacy Act, My Health Records Act, and relevant TGA requirements before implementation. Start with administrative workflows (scheduling, documentation) rather than clinical decision support until your team is confident in the system.
Outside help is most useful when the tool has to connect to existing systems, handle personal information, or be rolled out to a whole team. AI Lab Australia works with businesses across Sydney, Melbourne, Brisbane, Perth and Adelaide on that setup.
Alternatives to Deep Genomics
If Deep Genomics is not the right fit for your workflow, these tools serve a similar purpose and are worth evaluating:
Frequently Asked Questions About Deep Genomics
Can I subscribe to Deep Genomics software?
No. Deep Genomics is a drug discovery company, not a software vendor. Its BioFM platform supports its own programs and research partnerships. Organisations interested in working with it need to approach the company about a collaboration or licensing arrangement.
Is Deep Genomics relevant to Australian biotech companies?
It may be relevant to Australian biotech firms, universities and medical research institutes exploring genetic medicine discovery partnerships. For most other businesses it has no practical use. Any collaboration should address intellectual property ownership, data sharing and Australian ethics requirements from the outset.
What should Australian researchers check before sharing genomic data?
Genomic data is sensitive information under the Privacy Act 1988. Confirm consent covers the proposed use, obtain ethics approval under the National Statement on Ethical Conduct in Human Research, agree on de-identification, and document where data will be stored and who can access it overseas.
Ready to Implement Deep Genomics?
AI Lab Australia helps Australian businesses choose, set up and connect tools like Deep Genomics to the systems they already run, with privacy and data handling sorted before rollout.